You will be redirected to the website of our parent company, Schönherr Rechtsanwälte GmbH: www.schoenherr.eu
The Health Minister and the National Hospital Directorate General (OKFŐ) have announced a comprehensive reform of the Hungarian healthcare system aimed at shifting toward value-based financing, elevating care organisation to regional hubs (for populations of 1-2 million) and streamlining patient pathways. Supported by a planned HUF 500bln additional funding in the 2027 budget, hospital funding is expected to shift from volume-based to outcome-based metrics. Additionally, a new independent quality control authority will oversee both public and private providers starting in early 2027, while low-volume hospital departments will face regional consolidation starting with pilot talks in the Northern Great Plain.
The Hungarian government is preparing a sweeping policy shift to address systemic healthcare challenges. To reinstate performance incentives following the elimination of informal payments, hospital funding will tie 5 % (rising to up to 10 % over time) of additional resources directly to quality and outcome metrics. By early 2027, a new independent quality-control authority will begin supervising public and private care providers, collecting post-treatment patient feedback through independent third-party evaluations. Care organisation would shift towards regional centres serving 1-2 million residents, potentially resulting in the consolidation of departments such as maternity wards handling fewer than 200 births annually. Pilot discussions have reportedly begun in the Northern Great Plain region. The plans also include strengthening primary care for chronic conditions and adopting patient pathway management practices to help reduce waiting times.
The proposed changes could significantly affect healthcare regulation, financing and service delivery in Hungary. The new supervisory framework may introduce additional quality assurance and reporting requirements for healthcare providers. Regional consolidation could also require operational restructuring and changes to procurement and supply arrangements. Pharmaceutical and medical device suppliers may need to adapt their commercial strategies to changes in healthcare organisation and purchasing patterns.
Public hospitals and private healthcare providers, particularly those operating low-volume departments, may be directly affected by changes to hospital funding, quality oversight and regional care organisation. Healthcare investors, insurers, pharmaceutical companies and medical device suppliers may also be affected by changes to service provision and procurement arrangements.
Author: Bernadett Dobra